Kadimastem Ltd

Tel Aviv Stock Exchange KDST.TA

Kadimastem Ltd Revenue Per Share for the year ending December 31, 2023: USD 0.00

Kadimastem Ltd Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Kadimastem Ltd Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Kadimastem Ltd Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Kadimastem Ltd Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Kadimastem Ltd Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Tel Aviv Stock Exchange: KDST.TA

Kadimastem Ltd

CEO	Mr. Ronen Twito CPA
IPO Date	June 13, 2013
Location	Israel
Headquarters	Pinchas Sapir 7
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Key trends

Past 5 years